Translational Drug Development (TD2) is currently setting appointments to meet with our team at the SCRS West Clinical Tech & Innovation Summit. We welcome the opportunity to have in-depth conversations with you to learn more about your clinical research program and discuss ways to partner together.
Schedule time now to meet with our Site Engagement team.
You will also be able to meet us at Booth 35 during the networking breaks.
Have questions about how TD2 can assist with your regulatory needs? Reach out to our
expert staff today to get started.
Screening tools for the evaluation of a drug’s ability to cross various biological membrane systems in a microplate format.
Figure 7. Example of Caco-2 Assay results. Assessment of the permeability of either Metoprolol (highly Permeable) or Quinidine (PgP substrate). A cell monolayer grown on a filtered-well is used to evaluate test compound movement between the insert (apical compartment -A) and the plate well (basal compartment -B). Passive transport through the layer is determine by A-B flux, whereas active transporter will introduce a B-A distribution of compounds between the two compartments.
In vitro drug metabolism studies, are a screening mechanism to characterize drug metabolites, elucidate their pathways, to help with further in vivo testing.
Figure 5. Observes relationship between inhibitor
(Ketoconazole) and the substrate (Midazolam).
Figure 6. Inhibition Profile for CYP3A4
Protein binding assays assesses the degree to which drugs attaches to proteins within the plasma/tissue. A drug’s efficacy may be affected by the degree to which it binds. TD2 has validated this assay using the Rapid Equilibrium Device and analysis done by LC-MS.
Figure 3. The process of protein binding assessment with rapid equilibrium dialysis.
Figure 4. Protein binding analysis by equilibrium dialysis of plasma
across mutiple different speacies (mouse, rat, dog, monkely, human)
following exposure to multiple compounds.